AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 131 min read$TAK

Shannon Elaine Mary sold $68K of TAK

Shannon Elaine Mary (Pres., Global Supply & Quality) sold 3,978 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 on 2026-08-10.

Original reporting
SEC EDGAR · Shannon Elaine Mary
Published Aug 13, 2026, 1:42 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note the insider sale, but the filing does not provide new fundamental information that should drive repricing.

03

What to watch

Insider sales often reflect diversification, taxes, or personal liquidity needs; without additional context, this is not strong evidence of deteriorating fundamentals.

Relevance 3/10Novelty 2/10Timing: Filed 2026-08-12 for a sale dated 2026-08-10.

Background

The article is a SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Takeda’s Form 4 shows insider Shannon Elaine Mary sold 3,978 shares at $17.10 on 2026-08-10, totaling about $68.0K.

Expected impact

Likely negligible near-term impact; any effect would be limited to short-lived sentiment rather than fundamentals.

Evidence & confidence

The filing discloses a modest transaction size ($68,023.80) and does not include new company guidance, operational updates, or regulatory/legal developments.

Market effects

Sector

No clear sector read-through from a small, routine insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan could be interpreted by some traders as less “scheduled,” but the disclosed dollar value is still small.

Key entities

  • issuer
    Takeda Pharmaceutical Co Ltd

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Shannon Elaine Mary

    Pres., Global Supply & Quality, reported the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

AUG 24
$TAKMedAI 8/10

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.

thestarphoenix.com2 min
AUG 21
$TAKMedAI 8/10

Takeda Q1 adjusted EPS beats estimates despite slight sales dip

Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.

scanx.trade3 min
AUG 18
$TAKMedAI 8/10

This Newly Approved Narcolepsy Drug Is the First to Target the Sleep Disorder’s Root Cause Rather Than Its Symptoms

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

smithsonianmag.com4 min
AUG 8
$TAKMedAI 8/10

Takeda (TAK) Q1 2026 Earnings Call Transcript

Takeda (TAK) reported Q1 2026 revenue of JPY 1.22 trillion, up 10.2% on an actual FX basis but down 0.5% at constant rates, citing Vyvanse generic erosion offset by core brands. Core operating profit was JPY 358.9 billion and core EPS JPY 154. FY2026 guidance: revenue JPY 4.64 trillion, core op profit JPY 1.16 trillion, adjusted FCF JPY 650-750B. Orzeyful China approved; U.S./Japan expected in Q2 2026.

fool.com7 min